The adjuvanted respiratory syncytial virus (RSV) vaccine RSVPreF3 was immunogenic in lung transplant (LT) and allogeneic hematopoietic cell transplant (alloHCT) recipients. No vaccine-associated ...

Respiratory syncytial virus (RSV) is the leading cause of hospitalization in infants, with recent global estimates indicating that RSV causes tens of millions of lower respiratory tract infections and ...

Most children will contract RSV by the time they turn 2 years old. These preventative tips can help limit the spread. Respiratory syncytial virus (RSV) is a common—and extremely contagious—virus that ...

Respiratory syncytial virus (RSV) infection makes an impact on the epithelium that varies with age, promoting asthma in children and chronic obstructive pulmonary disease (COPD) in adults, according ...

RSV season is upon us. The most common reason infants are hospitalized in the US, respiratory syncytial virus is an infectious disease that causes a runny nose, inflamed airways, and a fever. In ...

ABRYSVO, a bivalent vaccine, maintained consistently high protective efficacy for both RSV A and RSV B disease through two seasons after a single dose. ABRYSVO efficacy was 77.8% against RSV lower ...

Respiratory viruses are more active from October through March. Use over-the-counter COVID tests and clinical tests to distinguish respiratory viruses. Health officials advise vaccines, testing and ...

Providing year-round access to RSV immunization would minimize the risk of large seasonal outbreaks across the nation, including in both urban and rural areas. That's according to a new study, ...